Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria

Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria IntroductionChronic spontaneous urticaria (CSU), which has generally replaced the former term chronic idiopathic urticaria (CIU), is defined by the presence of pruritic wheals (hives), angioedema, or both, that persist or recur for a period of at least 6 weeks and do not seem to be induced by any apparent external stimuli. The severity and duration of CSU may vary greatly among patients, while its impact on quality of life can be significant, especially in the presence of concurrent angioedema and when symptoms last for several years or fail to adequately respond to standard therapeutic interventions.According to the latest international guidelines, daily administration of nonsedating, second‐generation, H1‐antihistamines is the “gold‐standard” first‐line treatment of CSU, while dose‐escalation (up to fourfold the licensed daily dose) of H1‐antihistamines is typically followed as a second‐line approach when symptoms persist for more than 2 weeks after the initial treatment course. The use of sedating, first‐generation antihistamines for CSU treatment has been largely abandoned, particularly in Europe. Administration of these drugs (at bedtime only) is nevertheless included, as an alternative to dose advancement of H1‐antihistamines, in the US guidelines, while addition of another second‐generation antihistamine or an H2‐antagonist are among the second‐line treatment options recommended by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Dermatology Wiley

Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria

Loading next page...
 
/lp/wiley/treatment-response-to-omalizumab-in-patients-with-refractory-chronic-TH3MDG2qgq
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
International Journal of Dermatology © 2018 International Society of Dermatology
ISSN
0011-9059
eISSN
1365-4632
D.O.I.
10.1111/ijd.13935
Publisher site
See Article on Publisher Site

Abstract

IntroductionChronic spontaneous urticaria (CSU), which has generally replaced the former term chronic idiopathic urticaria (CIU), is defined by the presence of pruritic wheals (hives), angioedema, or both, that persist or recur for a period of at least 6 weeks and do not seem to be induced by any apparent external stimuli. The severity and duration of CSU may vary greatly among patients, while its impact on quality of life can be significant, especially in the presence of concurrent angioedema and when symptoms last for several years or fail to adequately respond to standard therapeutic interventions.According to the latest international guidelines, daily administration of nonsedating, second‐generation, H1‐antihistamines is the “gold‐standard” first‐line treatment of CSU, while dose‐escalation (up to fourfold the licensed daily dose) of H1‐antihistamines is typically followed as a second‐line approach when symptoms persist for more than 2 weeks after the initial treatment course. The use of sedating, first‐generation antihistamines for CSU treatment has been largely abandoned, particularly in Europe. Administration of these drugs (at bedtime only) is nevertheless included, as an alternative to dose advancement of H1‐antihistamines, in the US guidelines, while addition of another second‐generation antihistamine or an H2‐antagonist are among the second‐line treatment options recommended by

Journal

International Journal of DermatologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial